Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO)

[1]  T. Henry,et al.  Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials , 2018, European heart journal.

[2]  P. Nigro,et al.  Cell therapy for heart disease after 15 years: Unmet expectations , 2018, Pharmacological research.

[3]  F. Achilli,et al.  Cell Therapy for Refractory Angina: A Reappraisal , 2017, Stem cells international.

[4]  Jeroen J. Bax,et al.  Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long‐term results , 2017, Journal of interventional cardiology.

[5]  Doris A Taylor,et al.  Global position paper on cardiovascular regenerative medicine , 2017, European heart journal.

[6]  Peter A. Altman,et al.  Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart. , 2017, International heart journal.

[7]  M. Tendera,et al.  Effects of Transendocardial Delivery of Bone Marrow–Derived CD133+ Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina: Final Results of Randomized, Double-Blinded, Placebo-Controlled REGENT-VSEL Trial , 2017, Circulation research.

[8]  M. Capogrossi,et al.  Power Is Nothing Without Control: The Enduring Search for the Best Cell in Cardiac Cell Therapy at a Crossroads. , 2016, Circulation research.

[9]  Act Cmi Investigators.  Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study , 2016 .

[10]  Amit N. Patel,et al.  Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study , 2016, Cell transplantation.

[11]  T. Henry,et al.  The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. , 2016, JACC. Cardiovascular interventions.

[12]  B. Gersh,et al.  Revascularization in Patients With Severe Left Ventricular Dysfunction: Is the Assessment of Viability Still Viable? , 2016, Journal of the American College of Cardiology.

[13]  P. Stella,et al.  Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience , 2016, Netherlands Heart Journal.

[14]  T. Farid,et al.  Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis. , 2016, Circulation research.

[15]  K. Alexander,et al.  Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[16]  M. Drazner,et al.  Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review , 2015, Journal of the American Heart Association.

[17]  A. Biondi,et al.  Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy , 2015, BioMed research international.

[18]  M. Capogrossi,et al.  Bone Marrow Cell Therapy for Ischemic Heart Disease: The Never Ending Story. , 2015, Circulation research.

[19]  A. Bestetti,et al.  Novel Application of 3-Dimensional Real-Time Cardiac Imaging to Guide Stem Cell-Based Therapy. , 2015, The Canadian journal of cardiology.

[20]  E. Lansac,et al.  Spontaneous Coronary Artery Dissection Associated With Ascending Aortic Dystrophy: A Tear for Fear. , 2015, The Canadian journal of cardiology.

[21]  R. Sukmawan,et al.  Extracorporeal shockwave myocardial therapy is efficacious in improving symptoms in patients with refractory angina pectoris – a multicenter study , 2015, Coronary artery disease.

[22]  K. Anstrom,et al.  Predictors of Long‐term Clinical Endpoints in Patients With Refractory Angina , 2015, Journal of the American Heart Association.

[23]  C. Macaya,et al.  Selected CD133+ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina: Final Results of the PROGENITOR Randomized Trial , 2014, Circulation research.

[24]  Jeroen J. Bax,et al.  Predictors of response to intramyocardial bone marrow cell treatment in patients with refractory angina and chronic myocardial ischemia. , 2014, International journal of cardiology.

[25]  F. Achilli,et al.  The CD133+ cell as advanced medicinal product for myocardial and limb ischemia. , 2014, Stem cells and development.

[26]  T. Henry,et al.  Treatment of refractory angina in patients not suitable for revascularization , 2014, Nature Reviews Cardiology.

[27]  Darcy L. DiFede,et al.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.

[28]  J. Hodges,et al.  Long-term survival in patients with refractory angina. , 2013, European heart journal.

[29]  Hong Wang,et al.  Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials. , 2013, The Canadian journal of cardiology.

[30]  Jagmeet P. Singh,et al.  Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. , 2013, The American journal of cardiology.

[31]  S. Fisher,et al.  Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis , 2013, PloS one.

[32]  Y. Yoon,et al.  Revisiting cardiovascular regeneration with bone marrow‐derived angiogenic and vasculogenic cells , 2013, British journal of pharmacology.

[33]  M. Tendera,et al.  Paracrine proangiopoietic effects of human umbilical cord blood-derived purified CD133+ cells--implications for stem cell therapies in regenerative medicine. , 2013, Stem cells and development.

[34]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[35]  Dejian Lai,et al.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. , 2012, JAMA.

[36]  P. Coyte,et al.  Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines. , 2012, The Canadian journal of cardiology.

[37]  S. Dimmeler,et al.  Critical Reevaluation of Endothelial Progenitor Cell Phenotypes for Therapeutic and Diagnostic Use , 2012, Circulation research.

[38]  Scott D Flamm,et al.  A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). , 2011, American heart journal.

[39]  P. Währborg,et al.  Fatality, morbidity and quality of life in patients with refractory angina pectoris. , 2011, International journal of cardiology.

[40]  Peter A. Altman,et al.  Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi , 2011, American heart journal.

[41]  R. Perlingeiro,et al.  Clonal Analysis Reveals a Common Progenitor for Endothelial, Myeloid, and Lymphoid Precursors in Umbilical Cord Blood , 2010, Circulation research.

[42]  M. Pesce,et al.  GMP-based CD133+ cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy , 2009, Journal of cellular and molecular medicine.

[43]  Jeroen J. Bax,et al.  Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. , 2009, JAMA.

[44]  M. Pesce,et al.  Direct Minimally Invasive Intramyocardial Injection of Bone Marrow-Derived AC133+ Stem Cells in Patients with Refractory Ischemia: Preliminary Results , 2008, The Thoracic and cardiovascular surgeon.

[45]  H. Putter,et al.  CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms , 2007, Circulation.

[46]  T. Asahara,et al.  CD34-Positive Cells Exhibit Increased Potency and Safety for Therapeutic Neovascularization After Myocardial Infarction Compared With Total Mononuclear Cells , 2006, Circulation.

[47]  Jeroen J. Bax,et al.  Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results. , 2006, American heart journal.

[48]  M. Cerqueira,et al.  Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. , 2006, The American journal of cardiology.

[49]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[50]  C. Heeschen,et al.  Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. , 2005, Journal of molecular and cellular cardiology.

[51]  Chia‐cheng Chang,et al.  Accelerated growth and prolonged lifespan of adipose tissue-derived human mesenchymal stem cells in a medium using reduced calcium and antioxidants. , 2005, Stem cells and development.

[52]  R. Bolli,et al.  Cells Expressing Early Cardiac Markers Reside in the Bone Marrow and Are Mobilized Into the Peripheral Blood After Myocardial Infarction , 2004, Circulation research.

[53]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[54]  D. Berman,et al.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. , 1998, Circulation.

[55]  D. Berman,et al.  Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  D. Berman,et al.  Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. , 1993, Journal of the American College of Cardiology.

[57]  K. Miyazono,et al.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor , 1989, Nature.